Coagulopathy associated with COVID-19
■ Coagulopathy associated with COVID-19
1 – About 20%-55% of patients admitted to hospital for coronavirus disease 2019 (COVID-19) have laboratory evidence of coagulopathy
2 – COVID-19-associated coagulopathy appears to be prothrombotic
3 – Elevated d-dimer concentration is associated with poor clinical outcomes
4 – In the absence of a contraindication, patients admitted to hospital should receive venous thromboembolism prophylaxis as per standard of care
5 – Transfusion of blood products should be avoided in patients who do not have active, major bleeding
■ Five things to know about: Coagulopathy associated with COVID-19
S G Lee, M Fralick, M Sholzberg
CMAJ 2020, VOL 192 (21): e583
https://www.cmaj.ca/content/192/21/E583
■ Abnormal hemostatic parameters and risk of thromboembolism among patients with COVID-19 infection
R Castelli, A Gidaro
J Hematol 2020, vol 9 (1-2): 1-4
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188381/
■ Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline
Z Ye, B Rochwerg, Y Wang et al
CMAJ 2020, vol 192 (20): E536-E545
https://www.cmaj.ca/content/192/20/E536
■ Safety considerations with chroloquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection
D N Juurlink
CMAJ 2020, vol 192 (17): E450-E453
https://www.cmaj.ca/content/192/17/E450
■ Dr Paulo Fernando Leite
Cardiologia/Prevenção Cardiovascular
Estratificação de Risco Cardiovascular
Consultório: Rua Padre Rolim 815/sala 601 – Belo Horizonte/MG/Brasil
Tel: 33245518
CRMMG: 7026
Email: pfleite1873@gmail.com
Data: junho 2020